- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Dysgeusia.
Displaying page 1 of 1.
EudraCT Number: 2010-024425-20 | Sponsor Protocol Number: Esperanz-002 | Start Date*: 2011-03-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Leiden University Medical Centre | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular car... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: oral mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005588-29 | Sponsor Protocol Number: 1487-0001 | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm. V | |||||||||||||
Full Title: A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of sympt... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DK (Completed) NL (Prematurely Ended) PT (Completed) DE (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003366-39 | Sponsor Protocol Number: APHP200702 | Start Date*: 2020-10-16 |
Sponsor Name:Assitance Publique-Hopiaux de Paris | ||
Full Title: CAMOVID: A multicenter randomized trial to evaluate the efficacy and safety of camostat mesylate for the treatment of SARS-CoV-2 infection in ambulatory adult patients. | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001697-30 | Sponsor Protocol Number: COVIDNA | Start Date*: 2020-04-23 |
Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET | ||
Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) | ||
Medical condition: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000166-15 | Sponsor Protocol Number: IVM-2021-01 | Start Date*: 2021-03-03 |
Sponsor Name:Meditop Gyógyszeripari Kft | ||
Full Title: A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients | ||
Medical condition: COVID 19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-003403-33 | Sponsor Protocol Number: MIT-Co001-C101 | Start Date*: 2021-01-20 | |||||||||||
Sponsor Name:NEURALIS s.a. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of Estetrol (E4) for the Treatment of patients with Confirmed SARS-CoV-2 Infection | |||||||||||||
Medical condition: Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection with moderate COVID-19. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003936-25 | Sponsor Protocol Number: RLX0120 | Start Date*: 2020-10-31 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patie... | |||||||||||||
Medical condition: Adult paucisymptomatic COVID-19 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022648-19 | Sponsor Protocol Number: P05898 | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: A 26-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed episodes Associated With Bipolar I Disorder | |||||||||||||
Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005979-12 | Sponsor Protocol Number: XT-2002 | Start Date*: 2021-07-26 | |||||||||||
Sponsor Name:XENOTHERA | |||||||||||||
Full Title: An international, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy and safety of 150 mg XAV-19 infusion, in patients with moderate to severe COVID-19: the EUROXA... | |||||||||||||
Medical condition: Moderate to severe COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003102-26 | Sponsor Protocol Number: HIV-CORE007 | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Therapeutic vaccination: A Phase I/II Randomized, Placebo-Controlled Trial of ChAdOx1.tHIVconsvX prime-MVA.tHIVconsvX Boost Vaccination Regimen in Early-treated durably-controlling HIV-1 positive A... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001987-28 | Sponsor Protocol Number: PRECOV | Start Date*: 2020-05-06 | ||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | ||||||||||||||||||
Full Title: PRECOV: a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk | ||||||||||||||||||
Medical condition: Healthcare personnel at risk of SARS-CoV-2 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003757-28 | Sponsor Protocol Number: MEX-NM-301 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:Lupin Europe GmbH | |||||||||||||
Full Title: An Open-label, non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic Disorders | |||||||||||||
Medical condition: Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2); ICD-10 code G71.1 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003302-40 | Sponsor Protocol Number: WO40242 | Start Date*: 2018-04-10 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCA... | |||||||||||||
Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) BE (Completed) PT (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
